|Mechanism-based cancer therapy: resistance to therapy, therapy for resistance|
These include but are not limited to vemurafenib for the treatment of B-rapidly accelerated fibrosarcoma (BRAF) mutant melanoma28,29 and crizotinib for patients with anaplastic lymphoma receptor tyrosine kinase (ALK)-positive non-small-cell lung cancer ...
Nature.com - Mon, 29 Sep 2014 03:07
|Celldex Therapeutics (CLDX) Reports Publication of Glembatumumab Vedotin ...|
A number of cancers, including breast cancer, cutaneous and uveal melanoma, small cell lung cancer, osteosarcoma, renal cell cancer and glioblastoma overexpress gpNMB relative to normal tissue. Overexpression of gpNMB has been shown to promote the ...
StreetInsider.com (subscription) - Tue, 30 Sep 2014 13:03
|Abbvie announces multiple study results of veliparib investigational compound ...|
"There is an urgent need to develop novel treatment options for patients with squamous cell carcinoma," said Suresh S. Ramalingam, M.D., director, Division of Medical Oncology, Emory University. "These data demonstrate activity for veliparib in non ...
News-Medical.net - Mon, 29 Sep 2014 22:03
|Current Perspectives on HPV Vaccination|
Thirty years ago, human papillomavirus types 16 and 18 were isolated from cervical carcinomas, and it has been almost 10 years since the introduction of the first prophylactic virus-like particle (VLP) vaccine. The VLP vaccines have already impacted ...
Medscape - Tue, 30 Sep 2014 21:18
|How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic ...|
It has been reported that GAPDH overexpression is associated with cell proliferation via its effect on cyclin B-cdk1 activity.108 Moreover, in the case of abundant glucose, GAPDH links its substrate, glyceraldehyde-3-phosphate, liberating the small ...
Nature.com - Mon, 29 Sep 2014 03:05
|AstraZeneca Might Outperform Merck, Bristol-Myers In Cancer Therapy Market|
The studies evaluated the drug as a monotherapy, as well as a combination treatment with experimental drug tremelimumab, for the treatment of Non-small cell lung cancer (NSCLC). MEDI4736 is a PDL-1 inhibitor cancer therapy, which means it blocks the ...
Bidness ETC - Mon, 29 Sep 2014 04:48
|AstraZeneca Presents New Data From Investigational Cancer Drug Pipeline At ...|
NASDAQ - Sun, 28 Sep 2014 23:22
|AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress|
Cambridge Network - Sat, 27 Sep 2014 03:41
|Astrazeneca reports latest drug developments|
IFA Magazine - Mon, 29 Sep 2014 00:52
|You don't have to smoke to get lung cancer; group on a mission for a cure (VIDEO)|
Germaine, a woman who co-founded the Korum Automotive Group, a wonderful mother who also helped raise her first three grandchildren was diagnosed with small cell carcinoma. Thanks to treatment, she is still alive and pushing to help others just like her.
Q13 FOX - Thu, 25 Sep 2014 18:58
|P2X7 protein expression and polymorphism in non-small cell lung cancer ...|
P2X7, a purinergic receptor, plays important roles in inflammatory diseases, but recently its expression has been found in several tumors, suggesting a potential role as a cancer cell biomarker. Moreover, the relative amount of P2X7 varies among human ...
7thSpace Interactive (press release) - Mon, 01 Sep 2014 02:11